Loading…
Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide)
Background To evaluate the efficacy of timolol-dorzolamide drops used to decrease aqueous outflow from the eye on the prolongation of the biological activity of intravitreal bevacizumab. Methods Thirty-eight eyes of 38 patients with macular edema (ME) following retinal vein obstruction (RVO) were en...
Saved in:
Published in: | Graefe's archive for clinical and experimental ophthalmology 2009, Vol.247 (1), p.35-42 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
To evaluate the efficacy of timolol-dorzolamide drops used to decrease aqueous outflow from the eye on the prolongation of the biological activity of intravitreal bevacizumab.
Methods
Thirty-eight eyes of 38 patients with macular edema (ME) following retinal vein obstruction (RVO) were enrolled. These patients were randomly assigned into 2 groups: timolol-dorzolamide drops twice daily (n = 19) or no eyedrops (control; n = 19). All patients received 1.25 mg (in 0.05 mL) of bevacizumab intravitreally and were examined before treatment, 1 week after injection, and then every 4 weeks after injection. For each patient, visual acuity (VA), intraocular pressure (IOP), and central retinal thickness (CRT) by optical coherence tomography (OCT) were recorded before injection and at each visit after injection. The mean CRT at each timepoint was considered to directly reflect the biological activities of bevacizumab at those times.
Results
The mean CRT measured by OCT showed a significant decrease 1 week after treatment in both groups, and this difference was maintained for a total of 9 weeks (paired t-test, |
---|---|
ISSN: | 0721-832X 1435-702X |
DOI: | 10.1007/s00417-008-0917-1 |